CAMBRIDGE, Mass., Sept. 30, 2014 (GLOBE NEWSWIRE) -- Blueprint Medicines today announced that Kyle Kuvalanka, chief business officer, will present a company overview at the 13th Annual BIO Investor Forum on Tuesday, October 7, 2014 at 11:00 a.m. PDT at the Palace Hotel in San Francisco, CA.
About Blueprint Medicines
Blueprint Medicines is a patient-driven oncology company discovering and developing highly selective kinase inhibitors for genomically defined cancers. Led by a management team and advisors with world renowned expertise in cancer genomics, drug discovery and clinical oncology, Blueprint Medicines has developed a platform that combines genomics with a novel small molecule library of kinase inhibitors, enabling Blueprint Medicines to rapidly discover potent and highly selective drugs against clear drivers of diseases. Founded in 2011, Blueprint Medicines is privately held and initially backed by Third Rock Ventures and Fidelity BioSciences. For more information, please visit www.blueprintmedicines.com.
CONTACT: Investor Relations: Beth DelGiacco Stern Investor Relations, Inc. 212-362-1200 firstname.lastname@example.org Media Relations: David Polk Chandler Chicco Companies 310 309 1029 email@example.comSource: Blueprint Medicines